COVAXX, a division of United Biomedical, is responding to the COVID-19 breakout in a manner that is consistent with our values by following the science and putting diagnostics and solutions-thinking at the center of our approach. Our priority is to stay on the front lines to safeguard the health and well-being of our communities.

We have already deployed our antibody tests in several states in the U.S., China, and Taiwan. We are a high throughput antibody test and are actively working with communities and institutions to help detect and contain community spread.

In addition, COVAXX is developing the first Multitope Peptide-Based Vaccine that has shown promising efficacy in animals and is based on a commercially proven, safe and scalable vaccine platform. We are entering human trials later this summer.

Our mission and vision is to save and safeguard lives by tackling the global COVID-19 pandemic using cost-effective, scalable, and proven science-based solutions delivered to the world.